PDCD1 and melanoma: Anti-PD-1 monotherapy restored immune responses, which was reflected by an increase in Th1 cells in the peripheral blood of melanoma patients throughout six months of treatment (Figure 2A), which was not observed in the four patients analyzed receiving combination therapy with ipilimumab (Figure 2B).